Exam 4 Pathopharmacology: Antidepressants, Diabetes Mellitus, and Neurological Disorders

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/39

flashcard set

Earn XP

Description and Tags

Comprehensive review flashcards covering psychotropic pharmacology (SSRIs, SNRIs, TCAs, MAOIs, sedative-hypnotics), diabetes mellitus pathophysiology and therapeutics (insulins and oral antidiabetics), and acute neurological disorders (elevated ICP, TBI, strokes, and hematomas).

40 Terms

1
New cards

Electroconvulsive Therapy (ECT)

A non-pharmacological treatment for depression indicated when medications and psychotherapy have failed, when a rapid clinical response is necessary, for severely depressed or suicidal patients, and for elderly patients at imminent risk of starvation.

2
New cards

Vagus Nerve Stimulation

A treatment modality reserved for severe depression that is indicated exclusively after treatment failure with at least four different antidepressant drugs.

3
New cards

Selective Serotonin Reuptake Inhibitors (SSRIs)

The most widely prescribed class of antidepressants (introduced in 1987) that selectively inhibit serotonin reuptake to produce central nervous system excitation; they lack the hypotensive, sedative, anticholinergic, and cardiotoxic overdose profiles of tricyclic antidepressants.

4
New cards

Fluoxetine

The most widely prescribed SSRI in the United States (trade names Prozac and Sarafem), primarily indicated for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and premenstrual dysphoric disorder.

5
New cards

Serotonin Syndrome

A potentially fatal toxic state occurring 2 to 72 hours2\text{ to }72\text{ hours} after initiating serotonergic pharmacotherapy; manifestations include agitation, confusion, tachycardia, hypertension, dilated pupils, tremor, hyperreflexia, muscle rigidity, diaphoresis, and diarrhea.

6
New cards

Venlafaxine

A serotonin/norepinephrine reuptake inhibitor (SNRI, trade name Effexor) indicated for major depression, generalized anxiety disorder, and social phobia; it blocks norepinephrine and serotonin reuptake without blocking cholinergic, histaminergic, or α1\alpha_1-adrenergic receptors.

7
New cards

Duloxetine

An SNRI (trade name Cymbalta) with an elimination half-life of 12 hours12\text{ hours} that inhibits serotonin and norepinephrine reuptake and weakly inhibits dopamine reuptake; indicated for depression as well as neuropathic pain associated with diabetic peripheral neuropathy.

8
New cards

Tricyclic Antidepressants (TCAs)

Antidepressants that inhibit the neuronal reuptake of norepinephrine and serotonin; commonly cause sedation, orthostatic hypotension, and anticholinergic effects, with lethal cardiac conduction toxicity (dysrhythmias, atrioventricular blocks, ventricular fibrillation) as their most dangerous hazard in overdose.

9
New cards

Monoamine Oxidase Inhibitors (MAOIs)

Second- or third-line antidepressants (the drugs of choice for atypical depression) that cause irreversible inhibition of monoamine oxidase; they carry a severe risk of precipitating a hypertensive crisis if combined with dietary tyramine.

10
New cards

Bupropion

An atypical antidepressant (trade name Wellbutrin) that acts as a stimulant and appetite suppressant without affecting serotonergic, cholinergic, or histaminergic systems; it increases sexual desire, does not cause weight gain, but lowers the seizure threshold.

11
New cards

Flumazenil

A competitive benzodiazepine receptor antagonist administered parenterally to reverse sedation and respiratory depression during acute benzodiazepine toxicity or overdose.

12
New cards

Zaleplon

A pyrazolopyrimidine class sedative-hypnotic (trade name Sonata) indicated for the short-term management of insomnia; prolonged administration does not appear to trigger pharmacologic tolerance.

13
New cards

Eszopiclone

The S-isomer of zopiclone (trade name Lunesta), an oral non-benzodiazepine sedative-hypnotic approved for insomnia treatment without a federally designated restriction on treatment duration.

14
New cards

Type 1 Diabetes Mellitus

A metabolic disorder accounting for approximately 5%5\% of all diabetes cases, defined by autoimmune destruction of pancreatic β\beta cells (associated with specific HLA genes and autoantibodies) leading to absolute insulin deficiency and uninhibited glucagon production.

15
New cards

Type 2 Diabetes Mellitus

A progressive metabolic disorder representing 90% to 95%90\%\text{ to }95\% of diabetes cases, characterized by peripheral insulin resistance paired with relative secretory dysfunction of pancreatic β\beta cells.

16
New cards

Diagnostic Criteria for Diabetes Mellitus

Confirmed by meeting at least two of the following: a random blood glucose ≥200 mg/dL\ge 200\,\text{mg/dL} with classic symptoms, fasting plasma glucose ≥126 mg/dL\ge 126\,\text{mg/dL}, a 2-hour2\text{-hour} post-75 g75\,\text{g} oral glucose tolerance test value ≥200 mg/dL\ge 200\,\text{mg/dL}, or an HgbA1c≥6.5%\text{HgbA1c} \ge 6.5\%.

17
New cards

Diabetic Ketoacidosis (DKA)

An acute metabolic emergency arising from profound insulin deficiency, leading to accelerated lipolysis, formation of beta-hydroxybutyric and acetoacetic acids, severe metabolic acidosis, Kussmaul respirations, dehydration, and ketonuria.

18
New cards

Hyperosmolar Hyperglycemic State (HHS)

An acute complication occurring primarily in Type 2 DM characterized by severe hyperglycemia, extreme hyperosmolality, and severe dehydration without significant ketoacidosis or alteration in blood pH.

19
New cards

Insulin Lispro

A rapid-acting human insulin analog (Humalog) with an onset of action of 10 to 20 minutes10\text{ to }20\text{ minutes} and duration of 3 to 5 hours3\text{ to }5\text{ hours}, administered immediately before or directly after meals.

20
New cards

Regular Insulin

An unmodified, short-duration human insulin (Humulin R, Novolin R) with an onset of 30 to 60 minutes30\text{ to }60\text{ minutes}, a peak between 1 and 5 hours1\text{ and }5\text{ hours}, and an effective duration up to 10 hours10\text{ hours}; formulated as a clear solution.

21
New cards

NPH Insulin

An intermediate-duration human insulin preparation (Humulin N, Novolin N) formulated as a cloudy suspension; administered twice or three times daily via subcutaneous injection only and the only intermediate insulin suitable for mixing with short-acting insulins.

22
New cards

Insulin Glargine

A modified long-duration human insulin analog (Lantus) providing a prolonged, peakless duration of activity of up to 24 hours24\text{ hours} when injected subcutaneously once daily for basal glycemic control.

23
New cards

Metformin

A biguanide oral antihyperglycemic agent (Glucophage) that lowers blood glucose by decreasing hepatic gluconeogenesis and glycogenolysis, enhancing peripheral insulin sensitivity, and reducing intestinal glucose absorption.

24
New cards

Sulfonylureas

A class of oral antidiabetic agents (e.g., glipizide, glyburide) that directly stimulate functioning pancreatic β\beta cells to secrete insulin; used exclusively in Type 2 DM, with major side effects including hypoglycemia and weight gain.

25
New cards

Acarbose

An oral alpha-glucosidase inhibitor (Precose) that delays carbohydrate digestion and absorption in the small intestine; frequently causes flatulence, diarrhea, and abdominal cramps, and carries potential for hepatic dysfunction.

26
New cards

DPP-4 Inhibitors (Gliptins)

Oral antidiabetic medications (e.g., sitagliptin, saxagliptin, linagliptin) that inhibit dipeptidyl peptidase-4 to prolong the activity of incretin hormones, stimulating glucose-dependent insulin release and suppressing postprandial glucagon secretion.

27
New cards

Canagliflozin

A sodium-glucose co-transporter 2 (SGLT-2) inhibitor (Invokana) that blocks renal glucose reabsorption in the proximal tubules, inducing glucosuria; adverse effects include genital mycotic infections and urinary tract infections.

28
New cards

Exenatide

A glucagon-like peptide-1 (GLP-1) receptor agonist (Byetta) that mimics incretin action by slowing gastric emptying, stimulating glucose-dependent insulin release, suppressing glucagon secretion, and decreasing appetite; carries a risk of pancreatitis.

29
New cards

Pramlintide

A synthetic amylin mimetic (Symlin) administered subcutaneously prior to major meals to reduce postprandial blood glucose spikes by suppressing glucagon release and delaying gastric emptying.

30
New cards

Cerebral Autoregulation

The intrinsic homeostatic mechanism by which cerebral arterioles dilate or constrict to sustain adequate cerebral blood flow across fluctuations in blood pressure, regulated by arterial blood pHpH, PaCO2PaCO_2, and oxygen tension.

31
New cards

Intracranial Pressure (ICP)

The hydrostatic pressure exerted within the cranial vault by its three fixed volume compartments: brain tissue, blood volume, and cerebrospinal fluid (CSF); normal resting values range from 0 to 15 mm Hg0\text{ to }15\,\text{mm\,Hg}.

32
New cards

Brain Herniation

A catastrophic complication of uncontrolled elevated intracranial pressure characterized by mechanical protrusion and displacement of brain tissue through rigid internal dural openings or the foramen magnum.

33
New cards

Excitotoxic Calcium Overload

A cascade following ischemic brain injury wherein energy failure triggers uncontrolled glutamate release, activating NMDA channels and flooding neurons with intracellular calcium, driving enzymatic degradation, free radical production, and cell lysis.

34
New cards

Glasgow Coma Scale (GCS)

A clinical scoring system utilized to evaluate level of consciousness following acute brain injury based on eye opening, verbal responses, and motor responses, classified into mild (>12> 12), moderate (9 to 129\text{ to }12), and severe (<8< 8).

35
New cards

Decorticate and Decerebrate Posturing

Pathological motor postures in severe brain injury: decorticate (flexor) involves upper extremity flexion and lower extremity extension, while decerebrate (extensor) involves rigid extension of both upper and lower extremities and indicates deeper brainstem damage.

<p>Pathological motor postures in severe brain injury: decorticate (flexor) involves upper extremity flexion and lower extremity extension, while decerebrate (extensor) involves rigid extension of both upper and lower extremities and indicates deeper brainstem damage.</p>
36
New cards

Oculovestibular Reflex

A brainstem reflex assessed via the Doll's-eyes maneuver (oculocephalic testing) or cold calorics test; bilaterally unresponsive or absent responses provide diagnostic evidence of brainstem failure or brain death.

37
New cards

Epidural Hematoma

An arterial hemorrhage collecting between the inner skull table and the dura mater (most commonly from middle meningeal artery rupture); characteristically produces brief unconsciousness, followed by a lucid interval, and rapid secondary deterioration.

38
New cards

Subdural Hematoma

An intracranial bleed resulting from the shearing of bridging veins between the dura mater and the arachnoid membrane, manifesting acutely within 24 hours24\text{ hours} or subacutely between 2 and 10 days2\text{ and }10\text{ days} post-trauma.

39
New cards

Subarachnoid Hemorrhage (SAH)

Bleeding directly into the subarachnoid space due to ruptured cerebral aneurysms or arteriovenous malformations, producing blood spread within CSF, meningismus, cerebral vasospasm, and sudden excruciating headache.

40
New cards

Arteriovenous Malformation (AVM)

A congenital cerebral vascular malformation where embryonic capillaries fail to develop, creating high-flow direct fistulous connections from arteries into fragile veins that become engorged and prone to rupture.